

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation

先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1302)

VOLUNTARY ANNOUNCEMENT

LXible™ obtained official registration approval by the China NMPA

This announcement is made by LifeTech Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors with updated information in relation to the latest business and new product development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 2 September 2021, the Group’s self-developed LXible™ Left Atrial Appendage Occluder (“**LXible™**” or the “**Device**”) obtained official registration approval from the China National Medical Products Administration (“**NMPA**”).

Based on the LAmbre™ Left Atrial Appendage Occluder (“**LAmbre™**”), the Device has carried out a series of innovative design on the umbrella and the membrane. Being founded on the positive clinical feedback of LAmbre™, the safety and effectiveness of the Device have been further improved. At the same time, the Device can better meet the ever-increasing one-stop procedure that combines ablation of atrial fibrillation and left atrial appendage closure, reducing the pain of patients with atrial fibrillation and improving their clinical experience. The Group aims to deploy multiple generations of left atrial appendage occluders, and will continue to meet diversified clinical needs through LAmbre™ and LXible™.

The group will continue with independent innovation, and work with industry experts to advance the development and marketing of innovative medical device products to benefit patients.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
*Executive Director, Chairman
and Chief Executive Officer*

Hong Kong, 8 September 2021

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. JIANG Feng being the non-executive Director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.